Product delay hits Cedara profits
A product roll-out delay is the reason Cedara Software gave for its disappointing third quarter 2000 profits. The company's net loss was $119,000 (Canadian), compared to net income of $385,000 in the third quarter of 1999. Revenue for third
A product roll-out delay is the reason Cedara Software gave for its disappointing third quarter 2000 profits. The company's net loss was $119,000 (Canadian), compared to net income of $385,000 in the third quarter of 1999. Revenue for third quarter 2000 was $15.9 million, compared to $12.3 million for the same period a year earlier.
A new platform, the SNN 3.0, which integrates multiple surgical software systems, was not shipped to installed base customers until March 31, and was launched on the market immediately thereafter.
Cedara makes software for diagnostic imaging, image management, image-guided therapy, and cardiology. It recently released both Internet streaming software for medical imaging, called Cedara directDICOM, and Image Management Business for the PACS market.
Another factor affecting Cedara's earnings, according to a company statement, was losses for Surgical Navigation Specialists, in which Cedara has a minority interest. The company believes it will recover this loss from SNS profits in future quarters.
Cedara chairman and CEO Michael Greenberg said in a statement, "We have a backlog of orders for the SNN 3.0 platform. Despite the delay in shipping surgical systems, our R&D investment in growth markets is showing its potential."
Can a Six-Minute MRI Facilitate Detection of Multiple Sclerosis?
May 23rd 2025Recognition of the central vein sign with a six-minute MRI demonstrated comparable sensitivity for multiple sclerosis (MS) detection in comparison to oligoclonal band (OCB) assessment, which requires lumbar puncture, according to newly published research.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
